



Com|PI|i|t DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000

info@genekor.com www.genekor.com Tel. (+30) 210 6032138 Fax. (+30) 210 6032148 Scientific Director: George Nasioulas PhD

ΠΛΗΡΟΦΟΡΙΕΣ

Εξεταζόμενος:

ΑΜΚΑ:

Ημερ. Γέννησης:

Τύπος Δείγμ. #1: ΠΛΑΣΜΑ

Τύπος Δείγμ. #2:

Κωδικός Δείγμ. #1

Ημ. Συλλογής Δείγμ.:

Παραπέμπων:

Report No:

Ημερ. Παρ. Δειγμ.:

Ημερ. Αποτελ.:

Τύπος όγκου: ΚΑΡΚΙΝΟΣ ΜΑΣΤΟΥ

Com.PI.i.t. DX Liquid Biopsy Breast | Comprehensive Panel for Individualized Treatment

Περίληψη έκθεσης αποτελέσματος

12 Γονίδια αναλύθηκαν

1 Εγκεκριμένες θεραπείες που σχετίζονται με Βιοδείκτες για την ένδειξη

0 Θεραπείες με πιθανή αντίσταση που σχετίζονται με Βιοδείκτες

1 Γενωμικές αλλοιώσεις που ανιχνεύθηκαν στον όγκο

1 Θεραπείες με πιθανό όφελος που σχετίζονται με Βιοδείκτες

18 Κλινικές μελέτες που σχετίζονται με Βιοδείκτες

Αποτελέσματα και ερμηνεία*

Βιοδείκτης	Αποτέλεσμα	Εγκεκριμένες θεραπείες για την ένδειξη	Θεραπείες με πιθανό όφελος	Θεραπείες με πιθανή αντίσταση/τοξικότητα	Κλινικές μελέτες
PIK3CA	Exon 10 c.1633G>A (p.E545K)	Alpelisib+Fulvestrant (1A.1)	Everolimus (2C.1)		ναι

*Σημείωση: Το επίπεδο σημαντικότητας των παραλλαγών (Level of Evidence, LoE) (π.χ. 1A.1, 2C.1, 1B κλπ) βασίζονται στις οδηγίες για την αναφορά γενετικών παραλλαγών στον καρκίνο που δόθηκαν με κοινή συναίνεση των AMP, ACMG, ASCO και CAP. Για λεπτομερή περιγραφή των οδηγιών αυτών, ανατρέξτε στην Εικόνα 1.



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Com|PI|i|t DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000
 info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas
 PhD

Name:

Report No:

SAMPLE INFORMATION

Name:		Date Sp. Extracted:	
Medical ID:		Req. Physician:	
Date Of Birth:		Report No:	
Material #1:	PLASMA	Date Received:	
Material #2:		Date Of Report:	
Sample #1 ID:		Tumor type:	BREAST CANCER

Com.PI.i.t. DX Liquid Biopsy Breast | Comprehensive Panel for Individualized Treatment

Report Summary

12 Unique Genes analyzed	1 Genomic alterations identified in tumor
1 Biomarker related approved therapies for indication	1 Biomarker related therapies with potential benefit
0 Biomarker related therapies with potential resistance	18 Biomarker related Clinical Trials

Results and Interpretation*

Biomarker	Result	Approved therapies for indication	Therapies with potential benefit	Therapies with potential resistance/toxicity	Clinical Trials
PIK3CA	Exon 10 c.1633G>A (p.E545K)	Alpelisib+Fulvestrant (1A.1)	Everolimus (2C.1)	-	yes

*Note: Variants' Level of Evidence (LoE) (e.g. 1A.1, 2C.1, 1B etc) are based on the Joint consensus recommendation of AMP, ACMG, ASCO and CAP for reporting genetic variants in cancer. For a detailed description of the recommendation please refer to Fig. 1



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Com|PI|i|t DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000
 info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas
 PhD

Name:

Report No:

Genomic Alterations Identified

PIK3CA: c.1633G>A (p.E545K)

VAF*:1,5%

OncoKB

CIVIC

PMKB

Treatment information

Alpelisib in combination with fulvestrant is approved by the FDA for postmenopausal women, and men, with hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. Approval was based on the SOLAR-1 study (NCT02437318), a randomized, double-blind, placebo-controlled trial of alpelisib plus fulvestrant versus placebo plus fulvestrant. Among a subset of patients with PIK3CA mutations, the median PFS by local assessment was 11.0 months (95% CI, 7.5-14.5) for those who received the alpelisib combination compared with 5.7 months (95% CI, 3.7-7.4) for those who received placebo plus fulvestrant. Those results, assessed after a median follow-up of 20 months, translated into a 35% reduction in the risk of progression or death, with a hazard ratio of 0.65 in favor of alpelisib (95% CI, 0.50-0.85; P = .00065). There was no advantage to alpelisib on median PFS in patients without a PIK3CA mutation. PIK3CA activating mutations or amplification may predict sensitivity to inhibitors of the PI3K-AKTmTOR pathway. The mTOR inhibitor everolimus is FDA approved, in combination with the aromatase inhibitor exemestane, to treat postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. These therapies and other mTOR inhibitors are in clinical trials in breast cancer and other solid tumor types. Inhibitors of PI3K and AKT, alone or in combination with other therapies are also in clinical trials in solid tumors. Activating mutations in PIK3CA may also confer resistance to anti-HER2 therapies.

Gene information

PIK3CA is a gene that encodes the protein phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform, a subunit of the PI3K protein. Phosphatidyl 3-kinases (PI3K) are a family of lipid kinases involved in many cellular processes, including cell growth, proliferation, differentiation, motility, and survival. Mutant PIK3CA has been implicated in the pathogenesis of several cancers, including colon cancer, glioma, gastric cancer, breast cancer, endometrial cancer, and lung cancer ([PMID: 15016963](#)). PIK3CA mutations are positive prognostic factors in breast cancer. The somatic mutations found thus far in PIK3CA are oncogenic, and the majority of them are clustered within exon 10 and 21 (helical and kinase domains), with 80% of the identified mutations found within three hotspot: E542K, E545K, and H1047R ([PMID: 17376864, 21266528](#)). These mutations in PIK3CA lead to increased PI3K activity ([PMID: 22422409](#)), which may promote tumorigenesis in an AKT/mTOR-dependent or independent manner ([PMID: 19573809](#)).

Variant information

The PIK3CA p.Glu545Lys (E545K) detected in this patient is one of the most common PIK3CA hotspot mutations in multiple tumor types (<https://cancer.sanger.ac.uk/cosmic>). This alteration induces cellular proliferation, colony formation, cellular invasiveness, and conveys strong in vivo oncogenic potential.

*VAF: Variant Allele Frequency



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Com|PI|i+t DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000

info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas PhD

Name:

Report No:

Associated Treatments Information

Alpelisib

DrugBank

Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110a, which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer, are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019.

Alpelisib is indicated in combination with fulvestrant to treat postmenopausal women, and men, with advanced or metastatic breast cancer. This cancer must be hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and PIK3CA mutated. The cancer must be detected by an FDA-approved test following progression on or after an endocrine-based regimen.

Fulvestrant

DrugBank

Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer

For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.

Everolimus

DrugBank

Everolimus is a derivative of Rapamycin (sirolimus) and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)

 **Com|Pl|i|t DX Liquid**

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000

info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas
PhD

Name:

Report No:

anastrozole; indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease; indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib; indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery; indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Com|Pl|i|t DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000

info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas PhD

Name:

Report No:

Clinical Trials to consider

PIK3CA associated clinical trials

NCT04191499		Phase 2 Phase 3
Title	A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer	
Treatment	Inavolisib Placebo Palbociclib Fulvestrant	
Location	United States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Malaysia, New Zealand, Poland, Portugal, Russian Federation, Singapore, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom	

NCT05631795		Phase 4
Title	Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment	
Treatment	Alpelisib Fulvestrant	
Location	India	

NCT03264547		Phase 3
Title	A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab	
Treatment	Pertuzumab Trastuzumab Docetaxel Paclitaxel Eribulin	
Location	Japan	

NCT05090358		Phase 2
Title	Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer	
Treatment	Ketogenic Diet Low Carbohydrate Diet Alpelisib Fulvestrant Canagliflozin	
Location	United States	

NCT04524000		Phase 2
Title	Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer	
Treatment	Alpelisib Fulvestrant	



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Com|Pl|i|t DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000

info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas PhD

Name:

Report No:

Location	Japan
-----------------	-------

NCT04544189	Phase 2
Title	Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Treatment	Alpelisib Fulvestrant Placebo
Location	China

NCT05660083	Phase 2
Title	Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
Treatment	L-NMMA
Location	United States

NCT04589845	Phase 2
Title	Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Treatment	Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emtansine Idasanutlin Inavolisib Belvarafenib Pralsetinib
Location	United States, Australia, Belgium, Brazil, Canada, China, Denmark, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, Spain, Swaziland, Switzerland, Taiwan, United Kingdom

NCT03297606	Phase 2
Title	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Treatment	Olaparib Dasatinib Nivolumab plus Ipilimumab Axitinib Bosutinib Crizotinib Palbociclib Sunitinib Temezolimus Erlotinib Trastuzumab plus Pertuzumab Vemurafenib plus Cobimetinib Vismodegib Tucatinib
Location	Canada

NCT04317105	Phase 1 Phase 2
Title	Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
Treatment	Biopsy Biospecimen Collection Computed Tomography Copanlisib Hydrochloride Echocardiography Ipilimumab Nivolumab X-Ray Imaging
Location	United States, Canada



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Com|Pl|i|t DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000

info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas PhD

Name:

Report No:

NCT03939897		Phase 1 Phase 2
Title	Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer	
Treatment	Abemaciclib Copanlisib Hydrochloride Fulvestrant	
Location	United States	

NCT05768139		Phase 1 Phase 2
Title	First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor	
Treatment	STX-478 Fulvestrant	
Location	United States	

NCT03805399		Phase 1 Phase 2
Title	FUSCC Refractory TNBC Umbrella (FUTURE)	
Treatment	Pyrotinib with Capecitabine AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4) anti PD-1 with nab-paclitaxel PARP inhibitor included therapy BLIS with anti-VEGFR included therapy MES with anti-VEGFR included therapy mTOR inhibitor with nab-paclitaxel	
Location	China	

NCT03006172		Phase 1
Title	To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer	
Treatment	Inavolisib Fulvestrant Letrozole Palbociclib Metformin Trastuzumab Pertuzumab	
Location	United States, Canada, France, Spain, United Kingdom	

NCT05300048		Phase 1
Title	Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations	
Treatment	Serabelisib Insulin Suppressing Diet Nab paclitaxel	
Location	United States	

NCT05307705		Phase 1
Title	A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors	
Treatment	LOXO-783 Fulvestrant Imlunestrant Abemaciclib Anastrozole, Exemestane, or Letrozole Paclitaxel	



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Com|PI|i|t DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000

info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas PhD

Name:

Report No:

Location	United States, Australia, Canada, Japan, Singapore
-----------------	--

NCT05504213		Phase 1
Title	A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer	
Treatment	HS-10352 combined with fulvestrant (Stage 1) HS-10352 combined with fulvestrant (Stage 2)	
Location	China	

NCT05216432		Phase 1
Title	First-in-Human Study of Mutant-selective PI3K $\hat{\pm}$ Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer	
Treatment	RLY-2608 Fulvestrant	
Location	United States, Spain	

Press [here](#) for a live search of clinical trials for PIK3CA



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Com|Pl|i|t DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000
 info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas
 PhD

Name:

Report No:

Methodology

NGS analysis

DNA was extracted from the sample under investigation using the QIAamp Circulating Nucleic Acid Kit (Qiagen). Mutation hotspot regions of 12 genes were amplified using Oncomine Breast cell free total nucleic acid assay (Thermo Fisher Scientific). Copy number variations, SNPs, and indels were analyzed. Sequencing was carried out using the Next Generation Sequencing platform Ion GeneStudio S5 Prime System (ThermoFisher). The variant detection limit of the assay is 0.1%, with 90% sensitivity and >98% specificity for SNV hotspots and indels.

Genes Analyzed

10 gene alterations

AKT1	EGFR	ERBB2 (HER2)	ERBB3	ESR1	FBXW7	KRAS	PIK3CA	SF3B1	TP53
------	------	--------------	-------	------	-------	------	--------	-------	------

3 Copy number genes

CCND1	ERBB2 (HER2)	FGFR1				
-------	--------------	-------	--	--	--	--



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)

Com|Pli|t DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000
 info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas PhD

Name:

Report No:

Appendix




Figure 1. Joint consensus recommendation of AMP, ACMG, ASCO and CAP for reporting genetic variants in cancer. [1-2]

1. Leichsenring J, Horak P, Kreutzfeldt S, et al. Int J Cancer. 2019 Dec 1;145(11):2996-3010.
2. Li MM, Datto M, Duncavage EJ, et al. J Mol Diagn. 2017 Jan;19(1):4-23.



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Com|Pl|it DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000

info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas PhD

Name:

Report No:

References

- Francis G, Stein S. **Circulating Cell-Free Tumour DNA in the Management of Cancer.** Int J Mol Sci. 2015 Jun 19;16(6):14122-42. doi: 10.3390/ijms160614122. Review. (PMID: 26101870)
- Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. **Liquid biopsy: monitoring cancer-genetics in the blood.** Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. doi: 10.1038/nrclinonc.2013.110. (PMID: 23836314)
- Papadopoulou E, Tsoulos N, Tsantikidi K, Metaxa-Mariatou V, Stamou PE, Kladi-Skandali A, Kapeni E, Tsaousis G, Pentheroudakis G, Petrakis D, Lampropoulou DI, Aravantinos G, Varthalitis I, Kesisis G, Boukovinas I, Papakotoulas P, Katirtzoglou N, Athanasiadis E, Stavridi F, Christodoulou C, Koumariou A, Eralp Y, Nasioulas G. **Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.** PLoS One. 2019 Dec 20;14(12):e0226853. doi: 10.1371/journal.pone.0226853. eCollection 2019. (PMID: 31860648)
- Juric D, de Bono JS, LoRusso PM, Nemunaitis J, Heath EI, Kwak EL, Macarulla Mercad  T, Geuna E, Jose de Miguel-Luken M, Patel C, Kuida K, Sankoh S, Westin EH, Zohren F, Shou Y, Tabernero J. **A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3K  Isoform Inhibitor, in Patients with Advanced Solid Malignancies.** Clin Cancer Res. 2017 Sep 1;23(17):5015-5023. doi: 10.1158/1078-0432.CCR-16-2888. (PMID: 28490463)
- Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J. **Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.** Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. (PMID: 29793946)
- Rodon J, Bra a I, Siu LL, De Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, Eskens F, Bendell JC. **Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.** Invest New Drugs. 2014 Aug;32(4):670-81. doi: 10.1007/s10637-014-0082-9. (PMID: 24652201)
- Ndubaku CO, Heffron TP, Staben ST, Baumgardner M, Blaqui re N, Bradley E, Bull R, Do S, Dotson J, Dudley D, Edgar KA, Friedman LS, Goldsmith R, Heald RA, Kolesnikov A, Lee L, Lewis C, Nannini M, Nonomiya J, Pang J, Price S, Prior WW, Salphati L, Sideris S, Wallin JJ, Wang L, Wei B, Sampath D, Olivero AG. **Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a  -sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.** J Med Chem. 2013 Jun 13;56(11):4597-610. doi: 10.1021/jm4003632. (PMID: 23662903)
- Lopez S, Schwab CL, Cocco E, Bellone S, Bonazzoli E, English DP, Schwartz PE, Rutherford T, Angioli R, Santin AD. **Taselisib, a selective inhibitor of PI3KCA, is highly effective on PI3KCA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.** Gynecol Oncol. 2014 Nov;135(2):312-7. doi: 10.1016/j.ygyno.2014.08.024. (PMID: 25172762)
- Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rod n J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandrapaty S, Scaltriti M, Baselga J. **PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.** Sci Transl Med. 2015 Apr 15;7(283):283ra51. doi: 10.1126/scitranslmed.aaa4442. Erratum in: Sci Transl Med. 2018 Oct 24;10(464):. (PMID: 25877889)
- Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, Gonz lez-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL. **ER -dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.** Cancer Discov. 2011 Sep;1(4):338-51. doi: 10.1158/2159-8290.CD-11-0101. (PMID: 22049316)



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Com|PI|it DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000

info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas PhD

Name:

Report No:

11. Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. Phosphatidylinositol 3-Kinase \pm -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. *J Clin Oncol.* 2018 May 1;36(13):1291-1299. doi: 10.1200/JCO.2017.72.7107. [\(PMID: 29401002\)](#)
12. Juric D, Janku F, Rodan J, Burris HA, Mayer IA, Schuler M, Seggewiss-Bernhardt R, Gil-Martin M, Middleton MR, Baselga J, Bootle D, Demanse D, Blumenstein L, Schumacher K, Huang A, Quadt C, Rugo HS. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. *JAMA Oncol.* 2019 Feb 1;5(2):e184475. doi: 10.1001/jamaoncol.2018.4475. [\(PMID: 30543347\)](#)
13. Wen PY, Touat M, Alexander BM, Mellinshoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhi R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. *J Clin Oncol.* 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. [\(PMID: 30715997\)](#)
14. Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR. Characterization of the novel and specific PI3K \pm inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. *Mol Cancer Ther.* 2014 May;13(5):1117-29. doi: 10.1158/1535-7163.MCT-13-0865. [\(PMID: 24608574\)](#)
15. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chane P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, Garcia-Echeverria C, Sellers WR, Voliva CF. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. *Mol Cancer Ther.* 2012 Feb;11(2):317-28. doi: 10.1158/1535-7163.MCT-11-0474. [\(PMID: 22188813\)](#)
16. Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Pezza C, Xia C, Reif S, Genvresse I, Ramanathan RK. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. *Ann Oncol.* 2016 Oct;27(10):1928-40. doi: 10.1093/annonc/mdw282. [\(PMID: 27672108\)](#)
17. Vasudevan KM et al. **AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.** *Cancer Cell.* 2009 Jul 7;16(1):21-32. doi: 10.1016/j.ccr.2009.04.012. [\(PMID: 19573809\)](#)
18. Meric-Bernstam F et al. **PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.** *Clin Cancer Res.* 2012 Mar 15;18(6):1777-89. doi: 10.1158/1078-0432.CCR-11-2123. [\(PMID: 22422409\)](#)
19. Gymnopoulos M et al. **Rare cancer-specific mutations in PIK3CA show gain of function.** *Proc Natl Acad Sci U S A.* 2007 Mar 27;104(13):5569-74. doi: [\(PMID: 17376864\)](#)
20. Rudd ML et al. **A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.** *Clin Cancer Res.* 2011 Mar 15;17(6):1331-40. doi: 10.1158/1078-0432.CCR-10-0540. [\(PMID: 21266528\)](#)
21. Samuels Y et al. **High frequency of mutations of the PIK3CA gene in human cancers.** *Science.* 2004 Apr 23;304(5670):554. doi: 10.1126/science.1096502. [\(PMID: 15016963\)](#)
22. <https://civic.genome.wustl.edu/>
23. <http://cancer.sanger.ac.uk/>



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)



Com|P|i|t DX Liquid

Genekor Medical S.A. | 52, Spaton Ave., 15344, Gerakas, Athens, Greece, G.E.MI. nr: 0007856001000

info@genekor.com www.genekor.com Tel. (+30) 2106032138 Fax. (+30) 2106032148 Scientific Director: George Nasioulas
PhD

Name:

Report No:

24. <https://www.clinicaltrials.gov>

25. <http://atlasgeneticsoncology.org>

26. <https://www.oncokb.org/>

27. <https://www.mycancergenome.org/>

28. <https://pmkb.org/>



Electronically Signed by

- Angeliki Meintani, M.Sc., Chemist, AMKA:05049400525

- George Nasioulas, PhD Molecular Biologist, Scientific Director, AMKA:26025301255

Genekor a company certified with ELOT EN ISO 9001:2015 (Cert. No 041150049) and accredited under the terms of ELOT EN ISO 15189:2012 (Cert. No. 822)